Insight

Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC

Estela Rodriguez/ doctors.umiamihealth.org

Jan 25, 2025, 03:46

Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about a recent paper by Solange Peters et al. published in Journal of Thoracic Oncology:

“Long-term outcomes of Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC and tumor PD-L1 lower than 1% provides a long-term, durable clinical benefit, with or without chemotherapy, according to Peters S et al. via Journal of Thoracic Oncology.”

“Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis”

Authors: Solange Peters, Luis Paz-Ares, Martin Reck, Diederik Grootendorst, Suresh Ramalingam et al.

More posts featuring Estela Rodriguez.

cancer Diederik Grootendorst Estela Rodriguez ipilimumab Journal of Thoracic Oncology Luis Paz-Ares Martin Reck nivolumab NSCLC OncoDaily Oncology Solange Peters Suresh Ramalingam

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma